GTCM
CNTA

Gyon Technologies Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Gyon Technologies Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,426
Closed -$117K – 325
2021
Q4 		$117K Buy
+10,426
New +$140K 0.02% 539

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Gyon Technologies Capital Management's CNTA Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q1 2022, closing a stake of 10,426 shares — an estimated $117K sold.

Gyon Technologies Capital Management first reported a position in CNTA in Q4 2021 and held it in 1 quarter. The position peaked at $117K in Q4 2021. 44 funds tracked by Wall St. Rank hold CNTA as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Centessa Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 10,426 Centessa Pharmaceuticals shares in Q1 2022, an estimated $117K.
  • Gyon Technologies Capital Management first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Centessa Pharmaceuticals position peaked at $117K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.